Rapid clinical and EEG microstate changes 24 h after intranasal esketamine in major depressive disorder with suicidal ideation: a prospective paired study.
Journal of Affective Disorders July 23, 2026 DOI: 10.1016/j.jad.2026.122307 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Prospective paired study Peer reviewed |
|---|---|
| Population | Adults with major depressive disorder and suicidal ideation |
| Intervention | Intranasal esketamine |
| Duration | 24 hours |
| Measures | EEG microstates |
| Topics | Depression Esketamine |
| Key points | Intranasal esketamine was associated with rapid clinical improvement and concurrent changes in EEG microstates at 24 hours, suggesting a potential neurophysiological correlate of its rapid antidepressant and anti-suicidal effects. |
Abstract
Rapid clinical and EEG microstate changes 24 h after intranasal esketamine in major depressive disorder with suicidal ideation: a prospective paired study.
Comparable studies
Other observational and cohort studies on esketamine for depression, most cited first.
Citations in the library
Cites 9
- Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II) The International Journal of Neuropsychopharmacology August 26, 2020
- Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression New England Journal of Medicine October 4, 2023
- Ketamine: Mechanisms and Relevance to Treatment of Depression. Annual Review of Medicine September 20, 2023
- Divergent effects of ketamine and psilocybin on EEG power spectral density in a mismatch negativity paradigm Psychopharmacology November 5, 2025
- Efficacy of Oral Ketamine in Patients with Depression and Suicidality: A Retrospective Study. Indian Journal of Psychological Medicine January 22, 2026
and 4 more in the library